Dr Reddy’s gets DCGI’s nod for Zytorvi

SENSEX 74,197.72

+ 344.82

NIFTY 22,941.45

+ 52.50

CRUDEOIL 9,386.00

+ 75.00

GOLD 145,894.00

 -625.00

SILVER 209,030.00

 -2,455.00

SENSEX 74,197.72

+ 344.82

NIFTY 22,941.45

+ 52.50

NIFTY 22,941.45

+ 52.50

CRUDEOIL 9,386.00

+ 75.00

CRUDEOIL 9,386.00

+ 75.00

GOLD 145,894.00

 -625.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

The approval is for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

By G Naga Sridhar

Updated - October 21, 2026 at 10:47 AM. | Hyderabad

Dr. Reddy’s Laboratories CDSCO under the DCGI, have approved Zytorvi (toripalimab).

Dr. Reddy’s Laboratories on Wednesday said the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), have approved Zytorvi (toripalimab) in combination with cisplatin and paclitaxel.

The approval is for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories said, “As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”

Dr. Reddy’s entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries. 

Globally, Toripalimab is approved by regulatory authorities including the US Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), according to a release.

Published on October 21, 2026

Companies to follow

• Dr Reddys Laboratories Ltd

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers